Premium
Delay and completeness of cancer registration in a post‐marketing surveillance study of cimetidine
Author(s) -
Lucas T.,
Beresford J.,
Vessey M.
Publication year - 1993
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2630020308
Subject(s) - medicine , cimetidine , completeness (order theory) , postmarketing surveillance , pharmacoepidemiology , family medicine , medical physics , adverse effect , pharmacology , mathematical analysis , mathematics , medical prescription
Data collected in a large multicentre post‐marketing surveillance study of cimetidine have been used to assess delay and completeness of cancer registration. With regard to delay, 44% of registrations in Nottingham were received within 2 years of the diagnosis of cancer but only 14% in Oxford and 6% in Portsmouth. By the end of the third year, these figures had become 82%, 62% and 62% respectively. With regard to completeness, in the period 3 to 10 years before the assessment date 9% of Nottingham, 36% of Oxford and 17% of Portsmouth neoplasms were still unregistered. Investigators using National Cancer Registry data for interpretation of their studies should be acquainted with the performance of the individual registries concerned.